Liquidia Corporation - Common Stock (LQDA)
22.67
+0.29 (1.30%)
NASDAQ · Last Trade: Oct 27th, 11:38 AM EDT
Detailed Quote
| Previous Close | 22.38 |
|---|---|
| Open | 22.60 |
| Bid | 22.66 |
| Ask | 22.68 |
| Day's Range | 22.46 - 23.24 |
| 52 Week Range | 9.710 - 29.94 |
| Volume | 358,952 |
| Market Cap | 1.95B |
| PE Ratio (TTM) | -12.46 |
| EPS (TTM) | -1.8 |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 2,321,847 |
Chart
About Liquidia Corporation - Common Stock (LQDA)
Liquidia Corp is a biopharmaceutical company focused on the development and commercialization of innovative therapies for patients with rare and serious diseases. Utilizing its proprietary PRINT technology, Liquidia designs and manufactures novel drug formulations that enhance the delivery and effectiveness of established medications. The company is dedicated to addressing unmet medical needs by advancing its product pipeline, which targets various conditions, including pulmonary and cardiovascular diseases. Through its commitment to research and development, Liquidia aims to improve the quality of life for patients through more effective therapeutic options. Read More
News & Press Releases
MORRISVILLE, N.C., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its third quarter 2025 financial results on Monday, November 3, 2025. The company will host a webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update.
By Liquidia Technologies, Inc. · Via GlobeNewswire · October 27, 2025
MORRISVILLE, N.C., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that it will host a Research & Development Day (R&D Day) on Tuesday, October 28, 2025, in New York City which will be webcast from 2:00 p.m. to 4:30 p.m. Eastern Standard Time.
By Liquidia Technologies, Inc. · Via GlobeNewswire · October 7, 2025
MORRISVILLE, N.C., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases, announced today the company will present two oral presentations at the CHEST 2025 annual meeting on October 19-22, 2025, in Chicago. The company’s two presentations will focus on new data from its ASCENT trial pertaining to both the safety and exploratory efficacy of LIQ861 DPI treprostinil in PH-ILD patients through Week 16, and observed changes in the cardiac effort of PH-ILD patients.Oral Presentations include:Rapid Fire Oral Presentation, Tuesday, October 21, 2025, 10:20 a.m. – 10:24 a.m. CTTitle: Changes in Cardiac Effort in Pulmonary Hypertension-Interstitial Lung Disease: Insights from ASCENTPresenter: Dr. Dan Lachant - University of Rochester Medical CenterSession: On the Hunt for New Approaches to Diagnose and Monitor PHLate-Breaking Rapid Fire Oral Presentation, Tuesday, October 21, 2025, 1:52 p.m. – 1:57 p.m. CTTitle: Safety and Exploratory Efficacy Data of LIQ861 DPI Treprostinil in PH-ILD: ASCENT to Week 16Presenter: Dr. Nicholas Kolaitis - University of California, San Francisco (UCSF) Medical Center Session: Pulmonary Fibrosis: Advances in Pharmacotherapy Late-Breaking Scientific AbstractsUpon presentation, the slides will be available on the Publications page of Liquidia’s website located at https://liquidia.com/products-and-pipeline/publications.About ASCENT An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH (ASCENT), listed as ClinicalTrials.gov ID NCT06129240, will evaluate the safety and tolerability of LIQ861 in subjects who have WHO Group 1 and 3 pulmonary hypertension. Cohort A includes 54 subjects who have WHO Group 3 Pulmonary Hypertension associated with interstitial lung disease (PH-ILD). Additional cohorts from either Group 1 or Group 3 may be defined in future protocol amendments. Scheduled study visits to the clinic will occur at Screening, Baseline, Week 8, Week 16, Week 24, and Week 52. During this time, dose titration may be ordered at the Investigator's discretion and in accordance with the guidance provided. The primary objective of this study is to evaluate the safety and tolerability of LIQ861 in subjects with WHO Group 1 & 3 Pulmonary Hypertension (PH). The exploratory objectives of the study are to assess the effects of LIQ861 on exercise capacity, functional class, relevant biomarkers, and imaging assessments.About YUTREPIA™ (treprostinil) Inhalation PowderYUTREPIA is an inhaled dry-powder formulation of treprostinil delivered through a convenient, low-effort, palm-sized device. YUTREPIA is indicated for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) to improve exercise ability. YUTREPIA was designed using Liquidia’s PRINT® technology, which enables the development of drug particles that are precise and uniform in size, shape and composition, and that are engineered for enhanced deposition in the lung following oral inhalation. YUTREPIA was previously referred to as LIQ861 in investigational studies.About Liquidia CorporationLiquidia Corporation is a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease. The company’s current focus spans the development and commercialization of products in pulmonary hypertension and other applications of its proprietary PRINT® Technology. PRINT enabled the creation of Liquidia’s first approved product, YUTREPIA™ (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company is also developing L606, an investigational sustained-release formulation of treprostinil administered twice-daily with a next-generation nebulizer, and currently markets generic Treprostinil Injection for the treatment of PAH. To learn more about Liquidia, please visit www.liquidia.com.Cautionary Statements Regarding Forward-Looking Statements This press release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical facts, including statements regarding our future results of operations and financial position, our strategic and financial initiatives, our business strategy and plans and our objectives for future operations, are forward-looking statements. Such forward-looking statements, including statements regarding clinical trials, clinical studies and other clinical work (including the funding therefor, anticipated patient enrollment, safety data, study data, trial outcomes, timing or associated costs), regulatory applications and related submission contents and timelines, and our ability to execute on our strategic or financial initiatives, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives and financial needs. These forward-looking statements are subject to a number of risks discussed in our filings with the SEC, as well as a number of uncertainties and assumptions. Moreover, we operate in a very competitive and rapidly changing environment and our industry has inherent risks. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the future events discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Nothing in this press release should be regarded as a representation by any person that these goals will be achieved, and we undertake no duty to update our goals or to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise. Contact InformationInvestors:Jason Adair Chief Business Officer919.328.4350jason.adair@liquidia.comMedia: Patrick WallaceDirector, Corporate Communications919.328.4383patrick.wallace@liquidia.com
By Liquidia Technologies, Inc. · Via GlobeNewswire · September 29, 2025
MORRISVILLE, N.C., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that the company will present four posters at the Pulmonary Hypertension Professional Association (PHPN) Symposium taking place September 18 – 20, 2025, in Seattle.
By Liquidia Technologies, Inc. · Via GlobeNewswire · September 11, 2025
The company sells Tyvaso, a treatment for lung diseases. On Tuesday, Tyvaso showed promise, again, in a chronic condition.
Via Investor's Business Daily · September 2, 2025
MORRISVILLE, N.C., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that members of the company’s executive leadership team will be providing an update on the company's business during a fireside chat at the 2025 Wells Fargo Healthcare Conference on Wednesday, September 3, 2025, beginning at 3:45 p.m. ET in Boston.
By Liquidia Technologies, Inc. · Via GlobeNewswire · August 27, 2025
Via Benzinga · August 13, 2025
Liquidia Q2 sales hit $8.84 million after Yutrepia launch; PH-ILD study shows stable tolerability and improved walking distance at week 16.
Via Benzinga · August 12, 2025
The company is working through a patent battle that could seriously hamper sales of its new drug.
Via Investor's Business Daily · August 12, 2025
Via Benzinga · August 12, 2025
MORRISVILLE, N.C., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases, today announced its financial results for the second quarter ended June 30, 2025. The company will also host a webcast at 8:30 a.m. Eastern Time on August 12, 2025, to review financial performance and provide a corporate update.
By Liquidia Technologies, Inc. · Via GlobeNewswire · August 12, 2025
MORRISVILLE, N.C., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its second quarter 2025 financial results on Tuesday, August 12, 2025. The company will host a webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update.
By Liquidia Technologies, Inc. · Via GlobeNewswire · August 5, 2025
Shares are trading at a 25-year high ahead of what could be the first approval for a drug with a massive pipeline in front of it.
Via Investor's Business Daily · July 24, 2025
MORRISVILLE, N.C., June 23, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced the receipt of an additional $50.0 million under its sixth amendment to its financing agreement (HCR Agreement) with Healthcare Royalty (HCRx) upon the U.S. District Court for the Middle District of North Carolina denying United Therapeutics Corporation’s request for a preliminary injunction and temporary restraining order in its complaint filed against Liquidia and the first commercial sale of YUTREPIA™ (treprostinil) inhalation powder.
By Liquidia Technologies, Inc. · Via GlobeNewswire · June 23, 2025
Via Benzinga · June 10, 2025
Intrigued by the market activity in the middle of the day on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.
Via Chartmill · June 10, 2025
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Tuesday. Let's explore the market movements and identify the stocks with significant gaps.
Via Chartmill · June 10, 2025